Bioventus invests $15M in CartiHeal with option for acquisition

Alan Condon -   Print  |

Orthobiologics company Bioventus said July 16 that it has invested $15 million in CartiHeal and agreed on an option structure to acquire the company pending approval of its Agili-C implant. 

Three things to know:

1. CartiHeal has completed enrollment and outcome of interim analysis in an investigational device exemption study of Agili-C, an implant for the treatment of cartilage lesions in joints.

2. Bioventus will provide an additional $5 million to CartiHeal if required to complete the device exemption  study.

3. Terms of the deal to acquire CartiHeal were not disclosed.

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers